The MF market is growing due to increasing disease awareness and therapeutic innovation. Key players including Incyte (Jakafi), Sierra Oncology (momelotinib), and CTI BioPharma are advancing novel JAK inhibitors and targeted therapies that improve symptom management and overall survival. Diagnostic advancements and treatment guidelines are further optimizing patient care approaches for this rare hematologic malignancy. Access Full Report: https://shorturl.at/GFWha